Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
Phase 2
Recruiting
- Conditions
- DENV-3 Controlled Human Infection Model
- Interventions
- Drug: AV-1 100 mgDrug: AV-1 300 mgDrug: AV-1 900 mgDrug: Placebo
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- AbViro LLC
- Target Recruit Count
- 84
- Registration Number
- NCT06799741
- Locations
- 🇺🇸
Center for Immunization Research Inpatient Unit, Baltimore, Maryland, United States
🇺🇸Center for Immunization Research (CIR) JHBSPH, Baltimore, Maryland, United States
🇺🇸UVM Larner College of Medicine Department of MMG, Burlington, Vermont, United States
A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- AbViro LLC
- Target Recruit Count
- 42
- Registration Number
- NCT04273217
- Locations
- 🇺🇸
PPD Austin Clinic, 7551 Metro Center Drive, Suite 200, Austin, Texas, United States
News
No news found